EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Economic Profit
Net Operating Profit after Taxes (NOPAT)
Cash Operating Taxes
Invested Capital
Cost of Capital
Economic Spread Ratio
Economic Profit Margin

Merck & Co. Inc., economic profit calculation

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net operating profit after taxes (NOPAT)¹	16,744)	(714)	14,154)	13,349)	6,669)
Cost of capital²	7.70%	7.90%	7.88%	7.44%	7.39%
Invested capital³	79,426)	69,966)	73,942)	70,735)	57,182)

Economic profit⁴	10,627)	(6,242)	8,326)	8,083)	2,441)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ NOPAT. See details »

² Cost of capital. See details »

³ Invested capital. See details »

⁴ 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= 16,744 – 7.70% × 79,426 = 10,627

Download chart

Item	Description	The company
Economic profit	Economic profit is a measure of corporate performance computed by taking the spread between the return on invested capital and the cost of capital, and multiplying by the invested capital.	Merck & Co. Inc. economic profit decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc., NOPAT calculation

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income attributable to Merck & Co., Inc.	17,117)	365)	14,519)	13,049)	7,067)
Deferred income tax expense (benefit)¹	(1,249)	(1,899)	(1,568)	187)	(668)
Increase (decrease) in allowance for doubtful accounts²	1)	16)	10)	(5)	(1)
Increase (decrease) in LIFO reserve³	278)	269)	277)	(65)	(89)
Increase (decrease) in restructuring reserves⁴	(148)	199)	(124)	51)	(156)
Increase (decrease) in equity equivalents⁵	(1,118)	(1,415)	(1,405)	168)	(914)
Interest expense	1,271)	1,146)	962)	806)	831)
Interest expense, operating lease liability⁶	37)	40)	40)	40)	47)
Adjusted interest expense	1,308)	1,186)	1,002)	846)	878)
Tax benefit of interest expense⁷	(275)	(249)	(210)	(178)	(184)
Adjusted interest expense, after taxes⁸	1,033)	937)	792)	668)	693)
(Gain) loss on marketable securities	30)	(411)	462)	232)	(184)
Interest income	(415)	(365)	(157)	(36)	(59)
Investment income, before taxes	(385)	(776)	305)	196)	(243)
Tax expense (benefit) of investment income⁹	81)	163)	(64)	(41)	51)
Investment income, after taxes¹⁰	(304)	(613)	241)	155)	(192)
(Income) loss from discontinued operations, net of tax¹¹	—)	—)	—)	(704)	—)
Net income (loss) attributable to noncontrolling interest	16)	12)	7)	13)	15)
Net operating profit after taxes (NOPAT)	16,744)	(714)	14,154)	13,349)	6,669)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Elimination of deferred tax expense. See details »

² Addition of increase (decrease) in allowance for doubtful accounts.

³ Addition of increase (decrease) in LIFO reserve. See details »

⁴ Addition of increase (decrease) in restructuring reserves.

⁵ Addition of increase (decrease) in equity equivalents to net income attributable to Merck & Co., Inc..

⁶ 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= 1,159 × 3.20% = 37

⁷ 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= 1,308 × 21.00% = 275

⁸ Addition of after taxes interest expense to net income attributable to Merck & Co., Inc..

⁹ 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= 385 × 21.00% = 81

¹⁰ Elimination of after taxes investment income.

¹¹ Elimination of discontinued operations.

Download chart

Item	Description	The company
NOPAT	Net operating profit after taxes is income from operations, but after removement of taxes calculated on cash basis that are relevant to operating income.	Merck & Co. Inc. NOPAT decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc., cash operating taxes calculation

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Taxes on income from continuing operations	2,803)	1,512)	1,918)	1,521)	1,709)
Less: Deferred income tax expense (benefit)	(1,249)	(1,899)	(1,568)	187)	(668)
Add: Tax savings from interest expense	275)	249)	210)	178)	184)
Less: Tax imposed on investment income	81)	163)	(64)	(41)	51)
Cash operating taxes	4,246)	3,497)	3,760)	1,553)	2,510)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Cash operating taxes	Cash operating taxes are estimated by adjusting income tax expense for changes in deferred taxes and tax benefit from the interest deduction.	Merck & Co. Inc. cash operating taxes decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc., invested capital calculation (financing approach)

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Loans payable and current portion of long-term debt	2,649)	1,372)	1,946)	2,412)	6,431)
Long-term debt, excluding current portion	34,462)	33,683)	28,745)	30,690)	25,360)
Operating lease liability¹	1,159)	1,213)	1,294)	1,529)	1,662)
Total reported debt & leases	38,270)	36,268)	31,985)	34,631)	33,453)
Total Merck & Co., Inc. stockholders’ equity	46,313)	37,581)	45,991)	38,184)	25,317)
Net deferred tax (assets) liabilities²	(2,214)	(1,097)	1,292)	2,749)	121)
Allowance for doubtful accounts³	89)	88)	72)	62)	85)
LIFO reserve⁴	840)	562)	293)	16)	82)
Restructuring reserves⁵	564)	712)	513)	637)	603)
Equity equivalents⁶	(721)	265)	2,170)	3,464)	891)
Accumulated other comprehensive (income) loss, net of tax⁷	4,945)	5,161)	4,768)	4,429)	6,634)
Noncontrolling interests	59)	54)	67)	73)	87)
Adjusted total Merck & Co., Inc. stockholders’ equity	50,596)	43,061)	52,996)	46,150)	32,929)
Construction in progress⁸	(7,984)	(8,262)	(9,186)	(8,313)	(7,324)
Investments in debt and publicly traded equity securities⁹	(1,456)	(1,101)	(1,853)	(1,733)	(1,876)
Invested capital	79,426)	69,966)	73,942)	70,735)	57,182)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Addition of capitalized operating leases.

² Elimination of deferred taxes from assets and liabilities. See details »

³ Addition of allowance for doubtful accounts receivable.

⁴ Addition of LIFO reserve. See details »

⁵ Addition of restructuring reserves.

⁶ Addition of equity equivalents to total Merck & Co., Inc. stockholders’ equity.

⁷ Removal of accumulated other comprehensive income.

⁸ Subtraction of construction in progress.

⁹ Subtraction of investments in debt and publicly traded equity securities.

Download chart

Item	Description	The company
Invested capital	Capital is an approximation of the economic book value of all cash invested in going-concern business activities.	Merck & Co. Inc. invested capital decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc., cost of capital calculations

Dec 31, 2024

	Capital (fair value)¹	Weights					Cost of capital
Equity²	230,955)	230,955)	÷	264,714)	=	0.87	0.87	×	8.44%	=	7.36%
Loans payable and long-term debt, including current portion³	32,600)	32,600)	÷	264,714)	=	0.12	0.12	×	3.39% × (1 – 21.00%)	=	0.33%
Operating lease liability⁴	1,159)	1,159)	÷	264,714)	=	0.00	0.00	×	3.20% × (1 – 21.00%)	=	0.01%
Total:	264,714)					1.00					7.70%

Based on: 10-K (reporting date: 2024-12-31).

¹ US$ in millions

² Equity. See details »

³ Loans payable and long-term debt, including current portion. See details »

⁴ Operating lease liability. See details »

Dec 31, 2023

	Capital (fair value)¹	Weights					Cost of capital
Equity²	326,306)	326,306)	÷	359,519)	=	0.91	0.91	×	8.44%	=	7.66%
Loans payable and long-term debt, including current portion³	32,000)	32,000)	÷	359,519)	=	0.09	0.09	×	3.32% × (1 – 21.00%)	=	0.23%
Operating lease liability⁴	1,213)	1,213)	÷	359,519)	=	0.00	0.00	×	3.30% × (1 – 21.00%)	=	0.01%
Total:	359,519)					1.00					7.90%

Based on: 10-K (reporting date: 2023-12-31).

¹ US$ in millions

² Equity. See details »

³ Loans payable and long-term debt, including current portion. See details »

⁴ Operating lease liability. See details »

Dec 31, 2022

	Capital (fair value)¹	Weights					Cost of capital
Equity²	278,966)	278,966)	÷	306,960)	=	0.91	0.91	×	8.44%	=	7.67%
Loans payable and long-term debt, including current portion³	26,700)	26,700)	÷	306,960)	=	0.09	0.09	×	2.95% × (1 – 21.00%)	=	0.20%
Operating lease liability⁴	1,294)	1,294)	÷	306,960)	=	0.00	0.00	×	3.10% × (1 – 21.00%)	=	0.01%
Total:	306,960)					1.00					7.88%

Based on: 10-K (reporting date: 2022-12-31).

¹ US$ in millions

² Equity. See details »

³ Loans payable and long-term debt, including current portion. See details »

⁴ Operating lease liability. See details »

Dec 31, 2021

	Capital (fair value)¹	Weights					Cost of capital
Equity²	192,917)	192,917)	÷	230,146)	=	0.84	0.84	×	8.44%	=	7.07%
Loans payable and long-term debt, including current portion³	35,700)	35,700)	÷	230,146)	=	0.16	0.16	×	2.92% × (1 – 21.00%)	=	0.36%
Operating lease liability⁴	1,529)	1,529)	÷	230,146)	=	0.01	0.01	×	2.60% × (1 – 21.00%)	=	0.01%
Total:	230,146)					1.00					7.44%

Based on: 10-K (reporting date: 2021-12-31).

¹ US$ in millions

² Equity. See details »

³ Loans payable and long-term debt, including current portion. See details »

⁴ Operating lease liability. See details »

Dec 31, 2020

	Capital (fair value)¹	Weights					Cost of capital
Equity²	188,812)	188,812)	÷	226,474)	=	0.83	0.83	×	8.44%	=	7.03%
Loans payable and long-term debt, including current portion³	36,000)	36,000)	÷	226,474)	=	0.16	0.16	×	2.74% × (1 – 21.00%)	=	0.34%
Operating lease liability⁴	1,662)	1,662)	÷	226,474)	=	0.01	0.01	×	2.80% × (1 – 21.00%)	=	0.02%
Total:	226,474)					1.00					7.39%

Based on: 10-K (reporting date: 2020-12-31).

¹ US$ in millions

² Equity. See details »

³ Loans payable and long-term debt, including current portion. See details »

⁴ Operating lease liability. See details »

Merck & Co. Inc., economic spread ratio calculation, comparison to benchmarks

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit¹	10,627)	(6,242)	8,326)	8,083)	2,441)
Invested capital²	79,426)	69,966)	73,942)	70,735)	57,182)
Performance Ratio
Economic spread ratio³	13.38%	-8.92%	11.26%	11.43%	4.27%
Benchmarks
Economic Spread Ratio, Competitors⁴
AbbVie Inc.	-2.94%	-4.65%	4.79%	4.23%	-3.55%
Amgen Inc.	-0.04%	2.76%	7.34%	7.32%	11.64%
Bristol-Myers Squibb Co.	-22.32%	1.23%	-1.56%	0.76%	-14.75%
Danaher Corp.	-7.79%	-8.54%	-3.58%	-2.89%	-4.27%
Eli Lilly & Co.	15.12%	1.97%	9.33%	11.06%	17.74%
Gilead Sciences Inc.	-7.72%	5.41%	2.36%	9.07%	-4.00%
Johnson & Johnson	1.51%	-0.35%	4.92%	9.98%	4.78%
Pfizer Inc.	-3.47%	-9.56%	17.87%	11.05%	-3.61%
Regeneron Pharmaceuticals Inc.	21.22%	18.06%	23.41%	67.10%	38.60%
Thermo Fisher Scientific Inc.	-4.59%	-5.09%	-3.31%	-1.44%	-0.49%
Vertex Pharmaceuticals Inc.	-22.64%	11.31%	14.06%	15.27%	28.54%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Economic profit. See details »

² Invested capital. See details »

³ 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × 10,627 ÷ 79,426 = 13.38%

⁴ Click competitor name to see calculations.

Download chart

Performance ratio	Description	The company
Economic spread ratio	The ratio of economic profit to invested capital, also equal to the difference between return on invested capital (ROIC) and cost of capital.	Merck & Co. Inc. economic spread ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc., economic profit margin calculation, comparison to benchmarks

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit¹	10,627)	(6,242)	8,326)	8,083)	2,441)
Sales	64,168)	60,115)	59,283)	48,704)	47,994)
Performance Ratio
Economic profit margin²	16.56%	-10.38%	14.04%	16.60%	5.09%
Benchmarks
Economic Profit Margin, Competitors³
AbbVie Inc.	-3.61%	-5.84%	6.77%	7.22%	-8.04%
Amgen Inc.	-0.08%	7.18%	11.75%	12.12%	18.62%
Bristol-Myers Squibb Co.	-28.96%	1.85%	-2.43%	1.32%	-31.28%
Danaher Corp.	-24.04%	-28.04%	-8.89%	-7.21%	-12.52%
Eli Lilly & Co.	12.02%	1.70%	7.95%	10.21%	17.76%
Gilead Sciences Inc.	-11.96%	9.20%	3.99%	16.05%	-8.25%
Johnson & Johnson	1.81%	-0.41%	5.90%	10.44%	5.69%
Pfizer Inc.	-7.40%	-24.86%	19.56%	11.79%	-8.80%
Regeneron Pharmaceuticals Inc.	18.61%	16.47%	23.57%	45.37%	37.61%
Thermo Fisher Scientific Inc.	-8.78%	-10.16%	-6.11%	-2.93%	-0.92%
Vertex Pharmaceuticals Inc.	-18.58%	15.17%	20.74%	18.92%	37.46%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Economic profit. See details »

² 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Sales
= 100 × 10,627 ÷ 64,168 = 16.56%

³ Click competitor name to see calculations.

Download chart

Performance ratio	Description	The company
Economic profit margin	The ratio of economic profit to sales. It is the company profit margin covering income efficiency and asset management. Economic profit margin is not biased in favor of capital-intensive business models, because any added capital is a cost to the economic profit margin.	Merck & Co. Inc. economic profit margin deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc. (NYSE:MRK)

Economic Value Added (EVA)

Economic Profit

Net Operating Profit after Taxes (NOPAT)

Cash Operating Taxes

Invested Capital

Cost of Capital

Economic Spread Ratio

Economic Profit Margin